The AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020

Authors

  • Paola Raimondo Market Access Provider, Milano - Italia
  • Giorgio Casilli Market Access Provider, Milano - Italia
  • Martina Isernia Market Access Provider, Milano - Italia
  • Dario Lidonnici Market Access Provider, Milano - Italia
  • Roberto Ravasio Market Access Provider, Milano - Italia
  • Virginia Ronco Market Access Provider, Milano - Italia
  • Elena Lanati Market Access Provider, Milano - Italia

DOI:

https://doi.org/10.33393/grhta.2020.2173

Keywords:

AIFA, Drug access, Price and Reimbursement, Time-to-reimbursement

Abstract

Objective. To compare the time-to-reimbursement of the last two committees of the Italian Medicines Agency (AIFA), respectively appointed in 2015 and in 2018.

Methods. The analysis was run through a specific internal database created by MA-Provider. The database was populated with information regarding European Medicines Agency (EMA) approved new drugs, including each step of the Italian Price and Reimbursement (P&R) process reported in the monthly outcomes of Technical Scientific Committee (CTS) and Price and Reimbursement Committee (CPR) meetings from September 2015 to April 2020.

Results. The 2015 and the 2018 committees have reimbursed respectively 39 and 28 drugs by comparing their initial 19 months of activity. Significant differences have been observed in negotiated economic conditions, in particular an increase in the number of drugs with confidential discount (2018-committee: 96.4% vs 2015-committee: 64.1%; p = 0.003) and a reduction in the application of Managed Entry Agreements (MEAs) (2018-committee: 10.7% vs 2015-committee: 33.3%; p = 0.036). The average duration of the P&R procedure managed by the 2018-committee has increased by 45 days compared to the 2015-committee (287 days vs 242 days; p = 0.071) and this trend of delay is associated to the active scientific/economic assessment phase by CTS and CPR (particularly by the latter) and not to administrative phases (e.g. Official Journal publications).

Conclusions. The observed differences between committees may be explained by the higher number of oncological and/or innovative drugs assessed by the 2018-committee (regarding the time delay, probably linked to greater difficulties in finding a win-win agreement able to satisfy both AIFA and Pharmaceutical Company).

References

Lidonnici D, Ronco V, Isernia M, et al. Tempi di accesso ai farmaci in Italia nel periodo 2015-2017: analisi delle tempistiche di valutazione dell’Agenzia Italiana del Farmaco. Global & Regional Health Technology Assessment. 2018:1-9. DOI: https://doi.org/10.33393/grhta.2018.433

European Commission. Authorisation procedures - The centralised procedure. https://ec.europa.eu/health/authorisation-procedures-centralised_en (Data ultimo accesso: maggio 2020).

European Medicines Agency (EMA). Il sistema normativo europeo per i medicinali. Un approccio unitario alla regolamentazione dei medicinali in tutta l’Unione Europea. https://www.ema.europa.eu/en/documents/leaflet/european-regulatory-system-medicines-european-medicines-agency-consistent-approach-medicines_it.pdf (2016. Data ultimo accesso: maggio 2020).

European Federation of the Pharmaceutical Industries and Associations (EFPIA) Patient W.A.I.T. Indicator 2018 survey. https://www.efpia.eu/media/412747/efpia-patient-wait-indicator-study-2018-results-030419.pdf (2019. Data ultimo accesso: maggio 2020).

Agenzia Italiana del Farmaco (AIFA). Negoziazione e rimborsabilità. https://www.aifa.gov.it/pt/web/guest/negoziazione-e-rimborsabilit%C3%A0 (Data ultimo accesso: maggio 2020).

Data G, Mariani P. Market Access nel settore Healthcare. Strategie, attori, attività e processi. Franco Angeli. 2015:130.

European Medicines Agency (EMA). https://www.ema.europa.eu/en/medicines

Gazzetta Ufficiale Europea. https://eur-lex.europa.eu/oj/direct-access.html?locale=it

Gazzetta Ufficiale della Repubblica Italiana. https://www.gazzettaufficiale.it/ricerca/atto/serie_generale/originario?reset=true&normativi=false (Data ultimo accesso: maggio 2020).

Agenzia Italiana del Farmaco (AIFA). https://www.aifa.gov.it/ricerca?q=esiti+cts (Data ultimo accesso: maggio 2020).

Orphanet Report Series. Lists of medicinal products for rare diseases in Europe. https://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf (Data ultimo accesso: maggio 2020).

Agenzia Italiana del Farmaco (AIFA). Farmaci innovativi. https://www.aifa.gov.it/farmaci-innovativi (Data ultimo accesso: maggio 2020).

Health Industry. Sistemi sanitari e Market Access. Un dialogo difficile. SICS Editore. http://www.sicseditore.it/wp-content/uploads/2018/11/marketsaccess.pdf (2018. Data ultimo accesso: maggio 2020).

Agenzia Italiana del Farmaco (AIFA). Approfondimento sui Registri di Monitoraggio. http://www.farmacovigilanza.asl3.liguria.it/pdf/approfondimento_registri_monitoraggio.pdf (Data ultimo accesso: maggio 2020).

Morina M, Canti G, Damele F, et al. Nuovi criteri dell'Agenzia Italiana del Farmaco per l'attribuzione dell'innovatività terapeutica. Giornale Italiano di Farmacoeconomia e Farmacoutilizzazione. 2018;10:11-14.

Published

2020-12-14

How to Cite

1.
Raimondo P, Casilli G, Isernia M, Lidonnici D, Ravasio R, Ronco V, Lanati E. The AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020. Grhta [Internet]. 2020 Dec. 14 [cited 2021 Dec. 7];7(1):109-14. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/2173

Issue

Section

Original Research Article

Most read articles by the same author(s)

1 2 3 4 > >>